应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
VRTX 福泰制药
盘前交易 08-11 06:50:20 EDT
523.91
+27.84
+5.61%
盘前
525.00
+1.09
+0.21%
05:42 EDT
最高
546.17
最低
519.82
成交量
268.23万
今开
539.50
昨收
496.07
日振幅
5.31%
总市值
1,329亿
流通市值
1,329亿
总股本
2.54亿
成交额
14.19亿
换手率
1.06%
流通股本
2.54亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
智通财经 · 08-10 23:39
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
智通财经 · 08-10 23:39
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
异动解读|福泰制药盘中上涨9.21%,Q2业绩超预期叠加全年指引上调
行情直击 · 08-10 21:30
异动解读|福泰制药盘中上涨9.21%,Q2业绩超预期叠加全年指引上调
异动解读|福泰制药盘前上涨3.26%,Q2业绩超预期叠加多家机构上调目标价
行情直击 · 08-10 19:08
异动解读|福泰制药盘前上涨3.26%,Q2业绩超预期叠加多家机构上调目标价
异动解读|福泰制药盘中上涨3.05%,Q2营收超预期且上调全年指引
行情直击 · 08-04
异动解读|福泰制药盘中上涨3.05%,Q2营收超预期且上调全年指引
Vertex 扩大领导团队,为下一阶段增长注入强劲动力
投资观察 · 08-04
Vertex 扩大领导团队,为下一阶段增长注入强劲动力
非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元,Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场
智通财经 · 08-04
非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元,Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场
福泰制药重申2026年全年指引:GAAP与非GAAP研发、AI研发及销售管理费用预期不变
美股速递 · 08-04
福泰制药重申2026年全年指引:GAAP与非GAAP研发、AI研发及销售管理费用预期不变
AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税
美股速递 · 07-29
AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税
AbCellera携手福泰制药,共同开发针对自身免疫疾病的多特异性T细胞接合器
美股速递 · 07-29
AbCellera携手福泰制药,共同开发针对自身免疫疾病的多特异性T细胞接合器
财报前瞻|福泰制药本季度营收预计增11.23%,机构观点偏乐观
财报Agent · 07-27
财报前瞻|福泰制药本季度营收预计增11.23%,机构观点偏乐观
Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局
金吾财讯 · 07-13
Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局
福泰制药百亿美元并购透露了什么讯号?
蓝鲸财经 · 07-11
福泰制药百亿美元并购透露了什么讯号?
异动解读|福泰制药盘中下跌3.24%,百亿美元收购Crinetics引发市场消化压力
行情直击 · 07-09
异动解读|福泰制药盘中下跌3.24%,百亿美元收购Crinetics引发市场消化压力
大摩解读福泰制药百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间
智通财经 · 07-08
大摩解读福泰制药百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间
大摩解读福泰制药(VRTX.US)百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间
智通财经 · 07-08
大摩解读福泰制药(VRTX.US)百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间
RBC Capital上调福泰制药目标价至570美元
格隆汇 · 07-08
RBC Capital上调福泰制药目标价至570美元
Vera Therapeutics股价飙升:肾病新药获FDA批准
投资观察 · 07-08
Vera Therapeutics股价飙升:肾病新药获FDA批准
暴涨近99%!Crinetics获福泰制药拟100亿美元现金收购
老虎资讯综合 · 07-07
暴涨近99%!Crinetics获福泰制药拟100亿美元现金收购
100亿美元砸出史上最大收购:福泰制药(VRTX.US)溢价100%收购Crinetics(CRNX.US),杀入内分泌赛道
智通财经 · 07-07
100亿美元砸出史上最大收购:福泰制药(VRTX.US)溢价100%收购Crinetics(CRNX.US),杀入内分泌赛道
加载更多
公司概况
公司名称:
福泰制药
所属市场:
NASDAQ
上市日期:
--
主营业务:
Vertex Pharmaceuticals Incorporated于1989年在马萨诸塞州注册成立,是一家全球性的生物技术公司,致力于科学创新,旨在为患有严重疾病的个人,特别是在专业市场创造变革性药物。该公司已开发出针对囊性纤维化、镰状细胞病、输血依赖性β地中海贫血和急性疼痛等病症的获批疗法。该公司不断创新,推进跨越各种严重疾病的下一代临床和研究项目,包括IgA肾病和1型糖尿病等。
发行价格:
--
{"stockData":{"symbol":"VRTX","market":"US","secType":"STK","nameCN":"福泰制药","latestPrice":523.91,"timestamp":1786392000000,"preClose":496.07,"halted":0,"volume":2682319,"hourTrading":{"tag":"盘前","latestPrice":525,"preClose":523.91,"latestTime":"05:42 EDT","volume":118,"amount":61772.292,"timestamp":1786441365274,"change":1.09,"changeRate":0.002081,"amplitude":0.014182},"delay":0,"changeRate":0.05612111193984715,"floatShares":253718831,"shares":253718831,"eps":17.182146,"marketStatus":"盘前交易","change":27.84,"latestTime":"08-11 06:50:20 EDT","open":539.5,"high":546.17,"low":519.82,"amount":1418502022.5098,"amplitude":0.053118,"askPrice":546,"askSize":10,"bidPrice":520.12,"bidSize":1,"shortable":3,"etf":0,"ttmEps":17.182146,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786455000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":523.91,"preHourTrading":{"tag":"盘前","latestPrice":525,"preClose":523.91,"latestTime":"05:42 EDT","volume":118,"amount":61772.292,"timestamp":1786441365274,"change":1.09,"changeRate":0.002081,"amplitude":0.014182},"postHourTrading":{"tag":"盘后","latestPrice":523,"preClose":523.91,"latestTime":"19:51 EDT","volume":38619,"amount":20232655.2694,"timestamp":1786405872119,"change":-0.91,"changeRate":-0.001737,"amplitude":0.003417},"volumeRatio":1.9359870767149512,"impliedVol":0.2865,"impliedVolPercentile":0.296},"requestUrl":"/m/hq/s/VRTX","defaultTab":"news","newsList":[{"id":"2658930620","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658930620?lang=zh_cn&edition=full","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0256863811.USD","LU2236285917.USD","LU2089984988.USD","TBXU","IE00BJT1NW94.SGD","LU1035775433.USD","BIB","LU0234570918.USD","LU0289739699.SGD","LU1778281490.HKD","LU2456880835.USD","LU1674673691.USD","VRTX","GNMX","IE0002141913.USD","IE0002270589.USD","LU0889565916.HKD","LU1430594728.SGD","IE00B19Z9P08.USD","IE00BZ9MQY76.HKD","BK4585","SG9999001176.SGD","IE0009355771.USD","LU2324357040.USD","LU1093756168.USD","LU2417539215.USD","LU1069344957.HKD","PBE","IE00B19Z9Z06.USD","LU1674673428.USD","LU2362540622.SGD","IE00BFTCPJ56.SGD","IBBJ","SGXZ57979304.SGD","LU2362541513.USD","LU2462157665.USD","BK4588","BK4567","IBB","IBBQ","BBH","IDNA","LU1585245621.USD","LU0058720904.USD","SG9999001176.USD","LU0320765992.SGD","IE00B19Z3581.USD","BK4139","LU0417517546.SGD","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658793062","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658793062","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658793062?lang=zh_cn&edition=full","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周一,$福泰制药(VRTX)$(VRTX.US)早盘涨近7%,创历史新高;而竞争对手$Sionna Therapeutics(SION)$(SION.US)暴跌超90%,创记录新低。消息面上,SION表示,由于SION-719实验性囊性纤维化药物在中期临床试验中未能达到主要目标,公司将终止该药物的研发。投资者此前一直担忧SION可能对VRTX的核心囊性纤维化业务构成威胁,但此次试验失败消除了这一担忧。VRTX公司销售的Trikafta和Alyftrek用于治疗囊性纤维化——这是一种罕见、慢性且会缩短寿命的遗传性疾病,会导致肺部进行性损伤。","market":"sh","thumbnail":"https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478244.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B2B36J28.USD","IE00B19Z9Z06.USD","LU2362541273.HKD","IE00B894F039.SGD","LU2236285917.USD","BBH","LU0320765992.SGD","IE00B19Z3B42.SGD","BK4532","IE00BFTCPJ56.SGD","LU0417517546.SGD","PBE","BIB","VRTX","LU0256863811.USD","SGXZ57979304.SGD","LU2417539215.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","LU1674673428.USD","LU1093756168.USD","IDNA","IE00BJT1NW94.SGD","LU2456880835.USD","SG9999001176.SGD","GNMX","LU0109394709.USD","IBBQ","LU2462157665.USD","LU0061475181.USD","LU2468319806.SGD","LU0058720904.USD","LU0234570918.USD","BK4567","SG9999001176.USD","TBXU","IBB","IBBJ","LU1674673691.USD","LU1778281490.HKD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2362541513.USD","LU0079474960.USD","BK4139","SG9999013999.USD","IE00B19Z9P08.USD","LU1430594728.SGD","LU1585245621.USD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170275964","title":"异动解读|福泰制药盘中上涨9.21%,Q2业绩超预期叠加全年指引上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1170275964","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170275964?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:30","pubTimestamp":1786368641,"startTime":"0","endTime":"0","summary":"8月10日,福泰制药盘中上涨9.21%,报540.08美元/股,成交额1.14亿美元。消息面上,公司近日发布Q2财报,营收33.3亿美元超市场预期的32.3亿美元,同比增长12.5%;调整后EPS为4.73美元,同比增长4.6%。同时公司上调全年营收指引至131亿至132亿美元,高于此前的129.5亿至131亿美元及市场预期的130.6亿美元。此外,百亿美元收购Crinetics交易预计本季度完成,将新增内分泌业务支柱,进一步拓宽公司管线布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180549438","title":"异动解读|福泰制药盘前上涨3.26%,Q2业绩超预期叠加多家机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180549438","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180549438?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:08","pubTimestamp":1786360135,"startTime":"0","endTime":"0","summary":"8月10日,福泰制药盘前上涨3.26%,报515.0美元/股,成交额36.79万美元。消息面上,公司近日发布Q2财报,营收33.3亿美元超市场预期的32.3亿美元,同比增长12.5%;调整后EPS为4.73美元,同比增长4.6%。财报发布后,多家机构上调目标价:Cantor Fitzgerald上调至595美元,Rothschild上调至580美元,高盛此前已将目标价调升至652美元。此外,百亿美元收购Crinetics交易预计本季度完成,将新增内分泌业务支柱。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福泰制药盘前上涨3.26%,Q2业绩超预期叠加多家机构上调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104230011","title":"异动解读|福泰制药盘中上涨3.05%,Q2营收超预期且上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1104230011","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104230011?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:14","pubTimestamp":1785852884,"startTime":"0","endTime":"0","summary":"8月4日,福泰制药盘中上涨3.05%,报481.47美元/股,成交额1.49亿美元。消息面上,公司公布第二季度业绩:调整后每股收益4.73美元,同比增长4.65%,符合市场预期;营收33.34亿美元,同比增长12.5%,超出分析师预期的32.32亿美元约1亿美元。更为关键的是,公司将全年营收指引从此前的129.5亿至131亿美元上调至131亿至132亿美元,高于FactSet一致预期的130.6亿美元。业绩公布后,Cantor Fitzgerald将目标价从590美元上调至595美元,维持增持评级。此前高盛亦将目标价上调至652美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福泰制药盘中上涨3.05%,Q2营收超预期且上调全年指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117517951","title":"Vertex 扩大领导团队,为下一阶段增长注入强劲动力","url":"https://stock-news.laohu8.com/highlight/detail?id=1117517951","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117517951?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:02","pubTimestamp":1785844955,"startTime":"0","endTime":"0","summary":"宾夕法尼亚州普鲁士王,2026年8月4日——全球间接税与合规领域的“决策到防御”先锋,Vertex Inc.,今日宣布其领导团队迎来三位新成员,旨在为公司下一阶段的蓬勃发展提供坚实支撑。他们的加入,将通过对人才、区域运营及技术创新的领导力扩展,进一步强化 Vertex 的全球增长战略。在 Vertex,她将负责全球人才与企业文化战略,构建起推动业务规模化发展所需的人才储备和组织能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035775433.USD","LU2362541513.USD","LU2456880835.USD","LU1430594728.SGD","IE0002270589.USD","LU2089984988.USD","BK4555","IE0009355771.USD","BIB","BK4588","SGXZ57979304.SGD","LU0432979614.USD","IE00BJT1NW94.SGD","LU0823416689.USD","BK4533","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU1815336091.USD","LU2362540622.SGD","VRTX","LU1778281490.HKD","LU2237438978.USD","LU0417517546.SGD","BK4234","BK4023","IE0002141913.USD","BK4585","IE00B19Z3581.USD","PW","BK4084","BK4567","IBBQ","LU1559883803.SGD","LU0109394709.USD","LU1585245621.USD","LU0058720904.USD","SG9999001176.USD","LU1069344957.HKD","LU0061475181.USD","IDNA","LU0079474960.USD","03160","PBE","BK4604","IE00BFTCPJ56.SGD","TISI","LU2468319806.SGD","BK4099","BK4532","LU2362541273.HKD","SG9999013999.USD","LU0320765992.SGD","IE00B19Z9P08.USD","LU1093756325.SGD","IBB","LU0757428866.USD","LU0256863811.USD","LU2417539215.USD","GNMX","IE00BZ9MQY76.HKD","IE00B4R5TH58.HKD","LU2462157665.USD","IE00B19Z9Z06.USD","BK4120","LU1674673428.USD","IE00B2B36J28.USD","TM","SG9999001176.SGD","BBH","BK4139","LU1674673691.USD","LU2324357040.USD","VERX","LU0234570918.USD","TBXU","IE00B894F039.SGD","LU2236285917.USD","LU0566484027.USD","LU0289739699.SGD","LU1093756168.USD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539622","title":"非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元,Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656539622?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:59","pubTimestamp":1785833974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1585245621.USD","BIB","PBE","IE00B19Z9Z06.USD","IE00B19Z3B42.SGD","FRHC","BK4127","IDNA","IE00B19Z9P08.USD","GNMX","LU1093756325.SGD","LU0289739699.SGD","LU2468319806.SGD","KCE","BK4533","IPOS","IE00BJT1NW94.SGD","SGXZ57979304.SGD","BK4139","SG9999013999.USD","IBB","LU1778281490.HKD","VRTX","BK4588","IE00B4R5TH58.HKD","BK4585","LU0889565916.HKD","IE0002141913.USD","BBH","LTGO","LU0823416689.USD","LU0058720904.USD","REDS","IBBQ","IE00B19Z3581.USD","BK4532","IE00BJJMRZ35.SGD","LU2324357040.USD","LU1093756168.USD","LU1430594728.SGD","LU2362541273.HKD","LU2362541513.USD","TBXU","LU0256863811.USD","LU1674673428.USD","LU0417517546.SGD","IE00BFTCPJ56.SGD","LU2456880835.USD","LU0234570918.USD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126575276","title":"福泰制药重申2026年全年指引:GAAP与非GAAP研发、AI研发及销售管理费用预期不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1126575276","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126575276?lang=zh_cn&edition=full","pubTime":"2026-08-04 04:07","pubTimestamp":1785787669,"startTime":"0","endTime":"0","summary":"福泰制药(Vertex Pharmaceuticals)再次确认其2026年全年财务指引。在涵盖GAAP及非GAAP口径下的研发支出、AI研发投入以及销售、一般及管理费用(SG&A)方面,该公司均维持此前预期不变,未作出任何调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","SGXZ57979304.SGD","BK4139","IE00BJJMRZ35.SGD","BBH","IBBQ","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU1093756168.USD","LU2236285917.USD","IE00BZ9MQY76.HKD","BK4588","BK4567","SG9999013999.USD","LU0289739699.SGD","LU2362540622.SGD","LU1778281490.HKD","IE00B894F039.SGD","IE00B2B36J28.USD","LU0109394709.USD","BIB","BK4533","LU1430594728.SGD","IE0002141913.USD","LU0058720904.USD","LU1093756325.SGD","BK4585","LU1069344957.HKD","SG9999001176.USD","LU0417517546.SGD","LU0234570918.USD","LU2462157665.USD","LU0079474960.USD","IE00B4R5TH58.HKD","LU0432979614.USD","LU2089984988.USD","LU2237438978.USD","TBXU","GNMX","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","VRTX","LU2362541513.USD","LU1585245621.USD","LU1035775433.USD","LU0320765992.SGD","LU1674673428.USD","LU0061475181.USD","IBB","IDNA","LU0889565916.HKD","LU2417539215.USD","BK4532","IE0002270589.USD","LU2362541273.HKD","PBE","IE00B19Z3581.USD","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","LU0256863811.USD","LU1674673691.USD","LU0823416689.USD","LU2456880835.USD","IE0009355771.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185330982","title":"AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185330982","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185330982?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:06","pubTimestamp":1785323188,"startTime":"0","endTime":"0","summary":"AbCellera Biologics公司宣布,将收到一笔高达2800万美元的预付款。除此之外,还有里程碑付款以及阶梯式特许权使用费加持。这笔交易架构颇为复杂,既有前期现金注入,也有后续潜在收益。预付款即刻到账,为研发管线提供弹药。里程碑款项则与特定项目进展挂钩,分期兑现。至于阶梯式版税,会随着产品销售额的攀升而逐步增加。整体来看,这一支付安排既保障了短期资金流,又锁定了长期回报空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","IE00B4R5TH58.HKD","LU1778281490.HKD","IE00B19Z3581.USD","BIB","BK4532","IE00B894F039.SGD","BK4585","LU0320765992.SGD","BK4121","LU1674673428.USD","LU1093756168.USD","BK4588","LU1069344957.HKD","LU2362541513.USD","BK4533","ABCL","BK4567","LU0289739699.SGD","PBE","LU2462157665.USD","LU2236285917.USD","BK4139","IE0002270589.USD","IBBQ","LU0234570918.USD","LU2324357040.USD","LU2362541273.HKD","TBXU","LU1093756325.SGD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU1674673691.USD","LU1585245621.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","GNMX","IE00BZ9MQY76.HKD","BK4535","IDNA","SG9999013999.USD","VRTX","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0889565916.HKD","LU0432979614.USD","LU0109394709.USD","LU0058720904.USD","LU0417517546.SGD","LU1430594728.SGD","LU2456880835.USD","IE00B2B36J28.USD","LU0823416689.USD","LU2237438978.USD","SG9999001176.USD","LU0079474960.USD","BBH","IBB","IE0009355771.USD","LU2417539215.USD","IE0002141913.USD","LU0061475181.USD","LU1035775433.USD","LU2362540622.SGD","SGXZ57979304.SGD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147206442","title":"AbCellera携手福泰制药,共同开发针对自身免疫疾病的多特异性T细胞接合器","url":"https://stock-news.laohu8.com/highlight/detail?id=1147206442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147206442?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:01","pubTimestamp":1785322903,"startTime":"0","endTime":"0","summary":"AbCellera宣布与福泰制药达成合作,旨在共同探索和发现针对自身免疫性疾病及其他适应症的多特异性T细胞接合器。这一战略合作将结合双方的技术优势,致力于在治疗领域开拓创新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU2417539215.USD","IE0002141913.USD","IE00BJT1NW94.SGD","GNMX","LU1674673691.USD","IE00B4R5TH58.HKD","LU0432979614.USD","LU2462157665.USD","TBXU","IDNA","BK4139","LU0079474960.USD","IE00B19Z9Z06.USD","LU2362541513.USD","VRTX","IE00B19Z3B42.SGD","BK4567","IBB","BK4588","LU0823416689.USD","LU1093756168.USD","LU2236285917.USD","LU1674673428.USD","BBH","ABCL","LU1069344957.HKD","LU1035775433.USD","SGXZ57979304.SGD","LU0889565916.HKD","IE00B19Z9P08.USD","BK4533","LU0289739699.SGD","BK4121","LU2324357040.USD","LU0234570918.USD","LU0256863811.USD","SG9999013999.USD","BK4535","LU2237438978.USD","LU2362540622.SGD","LU0058720904.USD","PBE","LU0417517546.SGD","BK4532","IBBQ","IE00BFTCPJ56.SGD","LU0320765992.SGD","SG9999001176.SGD","LU2362541273.HKD","IE00B894F039.SGD","IE0009355771.USD","BIB","SG9999001176.USD","LU1093756325.SGD","IE0002270589.USD","BK4585","LU0061475181.USD","IE00BZ9MQY76.HKD","LU0109394709.USD","LU1430594728.SGD","LU2456880835.USD","IE00BJJMRZ35.SGD","LU1585245621.USD","IE00B2B36J28.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180578857","title":"财报前瞻|福泰制药本季度营收预计增11.23%,机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1180578857","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180578857?lang=zh_cn&edition=full","pubTime":"2026-07-27 08:08","pubTimestamp":1785110926,"startTime":"0","endTime":"0","summary":"福泰制药将于2026年08月03日发布季度财报,市场关注营收增长与并购后的利润表现。上季度营收29.87亿美元,同比增长7.82%;毛利率54.66%;归母净利润10.31亿美元,同比增长59.59%;净利率34.53%;调整后每股收益4.47美元,同比增长10.10%。本季度利润率端,若渠道与市场推广投入保持有序,可在维持处方增长的同时避免对毛利率产生过大扰动,结合上季度54.66%的毛利率基础,关注单位经济的微调空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|福泰制药本季度营收预计增11.23%,机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651117599","title":"Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2651117599","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651117599?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:10","pubTimestamp":1783951848,"startTime":"0","endTime":"0","summary":"金吾财讯 | Vertex Pharmaceuticals 与 Crinetics Pharmaceuticals 共同披露收购协议,企业将以每股 85 美元现金完成标的全额收购,交易对应 Crinetics 整体股权价值约 100 亿美元,扣除标的账面现金后净交易对价 88 亿美元,交易预计 2026 年第三季度完成,消息落地后 Crinetics 盘后股价实现翻倍上涨。Vertex 计划依托自有现金搭配债务工具完成交易资金筹措,美国银行、摩根士丹利提供 45 亿美元全额过渡性融资,收购落地后企业罕见病内分泌赛道产品矩阵将实现大幅扩容。","market":"us","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302497","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2417539215.USD","IDNA","LU0432979614.USD","LU1069344957.HKD","LU0061475181.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE0002270589.USD","LU1093756325.SGD","IBBQ","LU0109394709.USD","VERX","LU0256863811.USD","LU2362541273.HKD","PBE","IE0009355771.USD","BIB","BK4585","LU0079474960.USD","SG9999001176.SGD","LU1035775433.USD","IBB","LU2462157665.USD","IE00B894F039.SGD","BBH","LU1093756168.USD","LU2237438978.USD","CRNX","LU0566484027.USD","BK4588","LU0234570918.USD","IE00B2B36J28.USD","SG9999013999.USD","SG9999001176.USD","LU2362541513.USD","BK4532","LU1585245621.USD","IE00B19Z3581.USD","BK4007","IE00BJT1NW94.SGD","IE00BZ9MQY76.HKD","LU1778281490.HKD","IE00B19Z9Z06.USD","VRTX","LU0889565916.HKD","LU0757428866.USD","LU2362540622.SGD","IE00B4R5TH58.HKD","LU2456880835.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650760159","title":"福泰制药百亿美元并购透露了什么讯号?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650760159","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650760159?lang=zh_cn&edition=full","pubTime":"2026-07-11 22:55","pubTimestamp":1783781749,"startTime":"0","endTime":"0","summary":"01百亿美元级现金并购的底气福泰制药2025年全年营收120.01亿美元,同比增长9%,非GAAP净利润47.5亿美元,毛利率维持85%以上高位,账面现金及有价证券超过123亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783569458583958068","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4532","LU1069344957.HKD","LU1035775433.USD","IE00BFTCPJ56.SGD","IE00BZ9MQY76.HKD","MYLD","IE00B19Z9P08.USD","IE00BJJMRZ35.SGD","LU2324357040.USD","LU0289739699.SGD","VRTX","SG9999001176.SGD","LU0058720904.USD","KCE","LU1093756168.USD","LU1778281490.HKD","LU2417539215.USD","IE00BJT1NW94.SGD","BBH","IE00B2B36J28.USD","BK4567","SGXZ57979304.SGD","IE0002141913.USD","BK4588","IBBQ","LU1093756325.SGD","IBB","LU0320765992.SGD","BIB","IDNA","LU0234570918.USD","IE00B4R5TH58.HKD","LU0079474960.USD","LU2236285917.USD","PBE","IE00B19Z9Z06.USD","BK4139","IE0002270589.USD","XMMO","CALF","LU2362540622.SGD","LU0061475181.USD","IE00B19Z3581.USD","LU2462157665.USD","LU0823416689.USD","IE00B894F039.SGD","IE0009355771.USD","SG9999001176.USD","LU1585245621.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157031563","title":"异动解读|福泰制药盘中下跌3.24%,百亿美元收购Crinetics引发市场消化压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1157031563","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157031563?lang=zh_cn&edition=full","pubTime":"2026-07-09 01:37","pubTimestamp":1783532262,"startTime":"0","endTime":"0","summary":"7月8日,福泰制药盘中下跌3.24%,报505.32美元/股,成交额4.09亿美元。消息面上,福泰制药于7月7日宣布将以每股85美元现金收购Crinetics Pharmaceuticals,交易总股权价值约100亿美元,较后者收盘价溢价102%,为公司史上最大规模收购。福泰制药预计收购将于第三季度完成,2029年方可对调整后营业利润产生正贡献。此前交易公布当日福泰制药已跌超2%,当前跌幅为市场对收购成本及整合风险的进一步定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649299398","title":"大摩解读福泰制药百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2649299398","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649299398?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:01","pubTimestamp":1783512080,"startTime":"0","endTime":"0","summary":"摩根士丹利发布研报,对福泰制药以100亿美元收购Crinetics的交易进行解读。此次收购将为福泰制药新增第五大业务支柱——内分泌药物,补齐公司管线布局。根据公告,每股85美元的收购价格较Crinetics周一的收盘价溢价了102%。值得注意的是,摩根士丹利担任福泰制药的财务顾问,协助该公司达成收购Crinetics的协议。","market":"us","thumbnail":"https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464871.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大摩解读福泰制药(VRTX.US)百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBE","LU0058720904.USD","BBH","LU1674673691.USD","LU1732799900.SGD","LU2236285917.USD","LU1585245621.USD","LU0109394709.USD","IE0002270589.USD","LU2456880835.USD","IDNA","LU0210528500.USD","LU2111349929.HKD","LU1791710400.SGD","LU2237438978.USD","LU0267386448.USD","IE00BZ9MQY76.HKD","LU2133065610.SGD","LU0053666078.USD","BIB","LU0882574139.USD","LU0528227936.USD","LU2089284900.SGD","LU1363072403.SGD","LU2362540622.SGD","IE0009355771.USD","LU0432979614.USD","LU1720051108.HKD","IBB","SG9999001176.USD","IE00B19Z9P08.USD","BK4588","LU0079474960.USD","LU1720051017.SGD","LU2487616109.SGD","VRTX","KBWB","IE0002141913.USD","LU1244550221.USD","IAI","IE00B19Z3581.USD","LU0098860793.USD","BK4533","BK4581","IBBQ","LU0823416689.USD","LU2362541273.HKD","BK4139","LU0390134368.USD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649939579","title":"大摩解读福泰制药(VRTX.US)百亿收购Crinetics:补齐内分泌管线布局 两大核心药物打开增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2649939579","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649939579?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:40","pubTimestamp":1783510856,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1585245621.USD","IE00BJJMRZ35.SGD","BIB","BK4127","LU1720051017.SGD","LU2271345857.HKD","LU0795875169.SGD","LU1244550577.SGD","IBB","IE00B19Z3B42.SGD","LU0058720904.USD","BBH","LU1674673428.USD","KBWB","LU1430594728.SGD","PBE","IBBQ","LU0079474960.USD","LU1074936037.SGD","LU2362541273.HKD","LU2462157665.USD","SG9999001176.USD","LU0053666078.USD","LU0882574139.USD","IDNA","LU2417539215.USD","BK4139","LU0006306889.USD","LU2133065610.SGD","LU0417517546.SGD","LU2237438978.USD","SG9999001176.SGD","IAI","IE00B19Z3581.USD","LU0267386448.USD","SG9999013999.USD","LU0061475181.USD","LU2347655156.SGD","BK4567","LU0823416689.USD","LU1244550221.USD","LU2487616109.SGD","VRTX","LU1548497426.USD","LU2362540622.SGD","IE00B19Z9Z06.USD","LU0795875086.SGD","LU1668664300.SGD","LU2089283258.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649969921","title":"RBC Capital上调福泰制药目标价至570美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649969921","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649969921?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:24","pubTimestamp":1783499090,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2362540622.SGD","RY","GSIB","BIB","LU0320765992.SGD","LU2324357040.USD","UDN","IBB","LU0128525929.USD","BBH","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","LU0417517546.SGD","LU0289739699.SGD","LU1778281490.HKD","LU1093756168.USD","LU2462157665.USD","VRTX","BK4207","IDNA","IE0009355771.USD","IE00B2B36J28.USD","LU1069344957.HKD","LU2456880835.USD","LU2417539215.USD","IE00B894F039.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","IE00B19Z9Z06.USD","UUP","BK4567","LU0029864427.USD","BK4532","BK4139","IBBQ","LU0234570918.USD","LU2237438978.USD","IE00BJJMRZ35.SGD","LU0708994859.HKD","BK4533","LU0310800379.SGD","LU1267930573.SGD","BK4585","SG9999001176.USD","SGXZ57979304.SGD","LU0823416689.USD","SG9999013999.USD","PBE","LU1093756325.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111378876","title":"Vera Therapeutics股价飙升:肾病新药获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1111378876","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111378876?lang=zh_cn&edition=full","pubTime":"2026-07-08 02:47","pubTimestamp":1783450047,"startTime":"0","endTime":"0","summary":"周二,Vera Therapeutics, Inc.的股价上涨约8%,此前美国食品药品监督管理局批准了其用于治疗IgA肾病的药物。这款名为Trutakna的药物通过阻断两种蛋白质来发挥作用,这两种蛋白质会促使免疫系统产生抗体,这些抗体在肾脏中积聚并造成损伤。这是美国首个获批同时靶向这两种蛋白质的药物,尽管已有其他几种药物治疗该疾病。福泰制药正在研发一种同样能阻断这两种蛋白质的类似药物,FDA预计将在今年晚些时候对此做出裁决。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU2462157665.USD","IE00B4R5TH58.HKD","LU1674673428.USD","BK4139","IBBQ","LU0320765992.SGD","LU1035775433.USD","PBE","IE00B894F039.SGD","BK4533","IE00BZ9MQY76.HKD","IE00B19Z3B42.SGD","LU0432979614.USD","LU0256863811.USD","LU2362540622.SGD","VERA","LU1778281490.HKD","BK4585","SG9999013999.USD","LU1069344957.HKD","LU1093756168.USD","SG9999001176.USD","LU2362541513.USD","LU0889565916.HKD","LU0058720904.USD","IE00BFTCPJ56.SGD","IBB","IE00BJT1NW94.SGD","LU0109394709.USD","LU1585245621.USD","LU0823416689.USD","VRTX","IDNA","BK4588","LU0079474960.USD","LU0417517546.SGD","LU2324357040.USD","SG9999001176.SGD","LU1674673691.USD","LU1093756325.SGD","LU2456880835.USD","IE00BJJMRZ35.SGD","LU0061475181.USD","IE00B19Z3581.USD","BIB","IE0002270589.USD","LU0289739699.SGD","BK4532","IE00B19Z9Z06.USD","LABU","BK4539","IE00B2B36J28.USD","LU2236285917.USD","LU2237438978.USD","LU2362541273.HKD","IE00B19Z9P08.USD","SGXZ57979304.SGD","BK4567","BBH","IE0002141913.USD","LU2417539215.USD","LU1430594728.SGD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161465425","title":"暴涨近99%!Crinetics获福泰制药拟100亿美元现金收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1161465425","media":"老虎资讯综合","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161465425?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:52","pubTimestamp":1783432357,"startTime":"0","endTime":"0","summary":"7月7日,Crinetics美股盘中大幅上涨,涨近99%。消息面上,福泰制药同意以约100亿美元现金收购Crinetics,每股收购价为85美元,较Crinetics周一收盘价溢价约102%。受交易影响,福泰制药股价跌超2%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/ce70f982c0b1f1a2ba3407f02bcf893f","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/ce70f982c0b1f1a2ba3407f02bcf893f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX","CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649708736","title":"100亿美元砸出史上最大收购:福泰制药(VRTX.US)溢价100%收购Crinetics(CRNX.US),杀入内分泌赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2649708736","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649708736?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:35","pubTimestamp":1783384535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B2B36J28.USD","IBBQ","LU0109394709.USD","LU0289739699.SGD","LU1093756168.USD","IDNA","LU0234570918.USD","LU1093756325.SGD","CRNX","BK4007","IE0002270589.USD","LU0058720904.USD","LU0889565916.HKD","LU2456880835.USD","VRTX","LU2362540622.SGD","IBB","BK4533","LU0256863811.USD","BIB","SGXZ57979304.SGD","LU0823416689.USD","BK4585","LU2237438978.USD","IE00BJJMRZ35.SGD","LU2362541273.HKD","IE00BZ9MQY76.HKD","LU2417539215.USD","LU0432979614.USD","SG9999001176.SGD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU2324357040.USD","LU1674673691.USD","LU0417517546.SGD","BBH","LU0079474960.USD","PBE","LU1035775433.USD","IE00B4R5TH58.HKD","LU0061475181.USD","IE00B19Z3581.USD","LU1585245621.USD","LU1430594728.SGD","BK4588","IE00BJT1NW94.SGD","LU1778281490.HKD","SG9999001176.USD","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vrtx.com","stockEarnings":[{"period":"1week","weight":0.113},{"period":"1month","weight":0.0794},{"period":"3month","weight":0.1687},{"period":"6month","weight":0.1359},{"period":"1year","weight":0.4293},{"period":"ytd","weight":0.1556}],"compareEarnings":[{"period":"1week","weight":0.0203},{"period":"1month","weight":0.0239},{"period":"3month","weight":0.0472},{"period":"6month","weight":0.1172},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1336}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vertex Pharmaceuticals Incorporated于1989年在马萨诸塞州注册成立,是一家全球性的生物技术公司,致力于科学创新,旨在为患有严重疾病的个人,特别是在专业市场创造变革性药物。该公司已开发出针对囊性纤维化、镰状细胞病、输血依赖性β地中海贫血和急性疼痛等病症的获批疗法。该公司不断创新,推进跨越各种严重疾病的下一代临床和研究项目,包括IgA肾病和1型糖尿病等。","yearOnYearQuotes":[{"month":1,"riseRate":0.657143,"avgChangeRate":0.034393},{"month":2,"riseRate":0.457143,"avgChangeRate":0.001601},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.021959},{"month":4,"riseRate":0.6,"avgChangeRate":0.01636},{"month":5,"riseRate":0.571429,"avgChangeRate":0.076942},{"month":6,"riseRate":0.571429,"avgChangeRate":0.030748},{"month":7,"riseRate":0.457143,"avgChangeRate":-0.005619},{"month":8,"riseRate":0.638889,"avgChangeRate":0.047763},{"month":9,"riseRate":0.485714,"avgChangeRate":0.030192},{"month":10,"riseRate":0.542857,"avgChangeRate":0.000856},{"month":11,"riseRate":0.485714,"avgChangeRate":-0.02026},{"month":12,"riseRate":0.657143,"avgChangeRate":0.071588}],"exchange":"NASDAQ","name":"福泰制药","nameEN":"Vertex Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福泰制药,VRTX,福泰制药股票,福泰制药股票老虎,福泰制药股票老虎国际,福泰制药行情,福泰制药股票行情,福泰制药股价,福泰制药股市,福泰制药股票价格,福泰制药股票交易,福泰制药股票购买,福泰制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}